480.96
6.82 (1.44%)
| Previous Close | 474.14 |
| Open | 474.14 |
| Volume | 291,270 |
| Avg. Volume (3M) | 651,920 |
| Market Cap | 21,752,023,040 |
| Price / Earnings (TTM) | 18.25 |
| Price / Earnings (Forward) | 15.60 |
| Price / Sales | 7.49 |
| Price / Book | 3.18 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | 40.44% |
| Operating Margin (TTM) | 48.19% |
| Diluted EPS (TTM) | 25.11 |
| Quarterly Revenue Growth (YOY) | 17.20% |
| Quarterly Earnings Growth (YOY) | 5.10% |
| Total Debt/Equity (MRQ) | 2.94% |
| Current Ratio (MRQ) | 5.46 |
| Operating Cash Flow (TTM) | 1.41 B |
| Levered Free Cash Flow (TTM) | 825.79 M |
| Return on Assets (TTM) | 12.93% |
| Return on Equity (TTM) | 19.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | United Therapeutics Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.40 |
|
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Value |
| % Held by Insiders | 1.75% |
| % Held by Institutions | 100.69% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 600.00 (UBS, 24.75%) | Buy |
| Median | 525.00 (9.16%) | |
| Low | 423.00 (Wells Fargo, -12.05%) | Hold |
| Average | 514.00 (6.87%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 450.92 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 06 Nov 2025 | 600.00 (24.75%) | Buy | 454.00 |
| 29 Sep 2025 | 580.00 (20.59%) | Buy | 424.31 | |
| HC Wainwright & Co. | 30 Oct 2025 | 525.00 (9.16%) | Buy | 453.53 |
| RBC Capital | 30 Oct 2025 | 587.00 (22.05%) | Buy | 453.53 |
| 26 Sep 2025 | 569.00 (18.31%) | Buy | 432.66 | |
| Wells Fargo | 30 Oct 2025 | 423.00 (-12.05%) | Hold | 453.53 |
| Morgan Stanley | 10 Oct 2025 | 435.00 (-9.56%) | Hold | 440.00 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |